YEAR                        EVENTS
 1976 - The Company was incorporated in December, in the name of J.B.
        Mody Chemicals and Pharmaceuticals Ltd.  Later the name was
        changed to J.B. Chemical and Pharmaceuticals Ltd. and a fresh
        Certificate of Incorporation upon change of name was issued
 on
        21st August, 1985 by the Registrar of Companies, Maharashtra
 at
        Mumbai.
 
      - J.B. Chemicals and Pharmaceuticals Ltd. is the flagship of
 the
        `Unique' group of companies.  The Company was founded by Mr.
 J.B.
         Mody along with his two brothers, Mr. D.B. Mody and Mr. S.B.
         Mody.  It is engaged in the business of manufacturing bulk  
 
         drugs, intermediates, formulations, ayurvedic and herbal
         preparations.  
 
       - The Company's manufacturing facilities are situated at
 Thane,
         Belapur, Ankleshwar, Panoli and Daman.  
 
 1992 - The Company has commisioned its Soft Gelatine Capsules project
 at
        Panoli in Gujarat.  
 
 1993 - The Company issued 20,17,500 No. of Equity Shares of Rs. 10/-
        each as fully paid up bonus shares to the shareholders in the
 
        ratio of one bonus share for every two Equity Shares held by 
        capitalising a sum of Rs. 2,01,75,000/- from the Free Reserves
 of 
        the Company.
 
 1994 - The company allotted 20,17,500 No. of equity shares as fully
 paid
        bonus shares on December 1, 1993 by capitalisation of reserves
 to
        the tune of Rs. 201.75 lakhs.
 
 1996 - The Company during the past year has introduced many new
        formulations in the local market.  It has also increased its
 Bulk
        Drugs activity due to its R & D work and is able to increase
 its
        exports of Bulk Drug and formulations to various countries.
 
 1998 - The company has launched a slew of new drugs including
 products
        for vaginitis, gingivitis, periodontitis, pelvic inflammatory
        diseases and diarrhoea. Besides, it has also forged a
 technical
        collaboration with Fresenins GmbH, Austria for marketing
 their
        specialty products for chronic constipation, prehepatic and
        hepatic coma.
 
 1999 - J. B. Chemicals and Pharmaceutical Ltd is in talks with US
        consulting firms to help it enter the generic market for
        metronidazole and ranitidine in the US.
 
 2000 - JB Chemicals and Pharmaceuticals is merging pharma divisions
 of
        two other companies - Unique Pharmaceutical Laboratories
 (UPL)
        and Ifiunik Pharmaceuticals (IPL) - into itself.
 
 2002- JB Chemicals & Pharmaceuticals Ltd has informed that the
 following changes have taken place in the Directorship of the
 Company:
 
 1 Dr S Agarwala has resigned as a Director w e f March 08, 2002
 2 Mr Bansi S Mehta has resigned as alternate Director to Mr Vishnu D
 Patel w e f March 08, 2002
 3 Dr S Agarwala has been appointed as Alternate Director to Mr Vishnu
 D Patel w e f March 08, 2002
 4 Mr Bansi S Mehta has been appointed as Director in casual vacancy
 caused due to resignation of Dr S Agarwala w e f March 08, 2002.
 
 -J. B. Chemicals join hands with Neotherapeutics of USA.
 
 -JB Chem & Pharma and Neotherapeutics form JV to manage US Clinical
 Development, Regulatory Approvals and Marketing for JB Products.
 
 -: JB Chemicals & Pharmaceuticals has closed down its wholly owned
 subsidiary in Mauritius, which was floated in a bid to enhance its
 exports to European and other countries.
 
 2003
 
 -JBCPL files its first Abbreviated New Drug Application with the US
 Food and Drug Administration.
 
 -JBCPL becomes the first Indian Company to receive permission from
 drugs controllers General of India to market Rantac CD formulations.
 
 -JB Chem team up with White Chemicals for European generics Markets.
 
 -JB Chem appoints Dr Rajen Shah as the whole time Director on the
 board of the company.
 
 -The Company launches two new therapeutic products Cefjoy and Zudo
 for treatment of infections and health improvement.
 
 -Jb Chemicals & Pharmaceuticals Ltd. has informed that the equity
 shares of the company have been delisted by ASE w.e.f December 8,
 2003.
 
 2004
 
 -JB Chem bags US FDA approval for Panoli drug unit, Gujarat
 
 - Bags final approval from the United States Food and Drug
 Administration (US FDA), to manufacture and market ciprofloxacin
 tablets 250 mg, 500 mg and 750 mg in the US market.
 
 -JB Chemicals launches Magnilek, a MRI Contrast media
 
 
 2005
 
 - TGA Australia approves JBCPL’s tablet manufacturing facilities at
 Panoli, Gujarat, India.
 
 - JBCPL receives USFDA approval to market Fluconazole tablets in the
 US market.
 
 - JBCPL features in Forbes Asia Pacific 200 List for “Best under a
 Billion” for second year in a row.
 
 -Company has splits its Face value of Shares from Rs 10 to Rs 2
 
 2006
 
 - J. B. Chemicals enters into Product Development Agreement with Taro
 Pharmaceutical Industries Ltd.
 
 - JB Chemicals & Pharmaceuticals Ltd has announced that the Company
 has launched a new speciality division christened AUSTER (means south
 wind that bring health and prosperity).
 
 - JB Chemicals announces a Licensing Agreement with Gilead Sciences
 Inc for Manufacturing and Distribution of a Generic Version
 
 
 2007
 
 - JBCPL’s Annual Report for the year ended March 31, 2005 was awarded
 a merit certificate by the South Asian Federation of Accountants
 (SAFA), an apex body of SAARC, for the Best Presented Accounts for
 the year 2005 in the category of Hospitality, Health, Transport,
 Shipping, etc.
 
 - The Hon'ble High Court of Judicature of Bombay at Mumbai has
 sanctioned the Scheme of Amalgamation of Lekar Healthcare Ltd. with
 the Company.
 
 
 2008
 
 - JB Chemicals & Pharmaceuticals Ltd has informed that the Unique
 Pharmaceutical Laboratories (A Div of J B Chemicals & Pharmaceuticals
 Ltd) are to announce receiving one more international quality
 accreditation for their pharmaceutical manufacturing facility at
 Panoli, Gujarat.
 
 - Strategic investment in a company in South Africa called Biotech
 Laboratories.
 
 
 2009
 
 - JB Chem&Phrm - J.B. Chemicals receives US FDA approval for
 Diclofenace Sodium Tablets.
 
 
 2010
 
 - JB Chemicals - Board recommends dividend.
 
 - JB Chem&Phrm - J.B. Chemicals receives US FDA approval for
 Diclofenace Sodium Tablets.
 
 
 2011
 
 - Divested the OTC portfolio in Russia, Ukraine and CIS to J&J.
 
 - JB Chem&Phrm - J. B. Chemicals launches a New Domestic Division.
 
 -JB Chem&Phrm - J.B. Chemicals announces completion of its
 transaction of Sale of Russia-CIS OTC Business to Cilag GmbH Intern.
 
 - JB Chem&Phrm - J.B.Chemicals declares handsome onetime special
 dividend.
 
 
 2012
 
 - JB Chem&Phrm - Board recommends Dividend